Droplet Biosciences develops sensitive cancer diagnostics by leveraging lymphatic fluid accessed via a non-invasive process that collects surgical drain fluid after tumor resection. The company says this lymphatic fluid, rich in T-cells, proteins, and other biomarkers, can reveal the body’s immune response to cancer earlier and with greater sensitivity than blood. Its first clinical application targets detection of residual disease in head and neck cancer patients immediately after surgery. Founded in 2021 in Cambridge, MA, the company was started by CEO Theresa Tribble and CSO Wendy Winckler, PhD, along with scientific co-founders Jose P. Zevallos, MD, MPH; Eugene N. Myers, M.D., Chair of Otolaryngology at the University of Pittsburgh and UPMC; and Aadel Chaudhuri, MD, PhD. The company raised $8M in Seed funding and intends to use the proceeds to accelerate its development efforts.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2023